Guidance on the process for ending a clinical trial.
Similar Posts
Isotretinoin – updates to prescribing guidance and survey of services
The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking further information from dermatology services who prescribe isotretinoin to inform any future changes to current risk minimisation measures.
Chris Kessler: How access to innovative rare therapies can transform the lives of children like Charlie
A story of hope, medical innovation, and the impact of effective regulation on access to treatment.
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).
MHRA seizes 7.7 million doses of illegal medicines and removes hundreds of illegal online listings as part of Operation Pangea
Operation Pangea brings together health regulators, customs authorities, law enforcement agencies, and private sector partners to tackle the threat posed by global criminal networks
Field Safety Notices: 6 October to 10 October 2025
List of Field Safety Notices from 6 October to 10 October 2025.